TY - JOUR
T1 - Antiglycolipid antibodies in motor neuropathies
AU - Baumann, Nicole
AU - Harpin, Marie Luce
AU - Marie, Yannick
AU - Lemerle, Karine
AU - Chassande, Benedicte
AU - Bouche, Pierre
AU - Meininger, Vincent
AU - Yu, Robert K.
AU - Léger, Jean Marc
N1 - Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 1998
Y1 - 1998
N2 - In peripheral neuropathies with monoclonal gammopathy, mainly IgM, it appears clear from clinical, electrophysiological, and experimental data, that the target glycolipid or glycolipid epitope for the IgM is related to the type of neuropathy - purely sensory, predominantly sensory, or uniquely motor. Investigations have focused on chronic peripheral neuropathies associated with polyclonal IgM reactivity to glycolipids. Although IgM anti-GM1 antibodies are present in normal controls, there is a subgroup of motor neuropathies with high titer anti-GM1 antibodies, mainly multifocal neuropathies with conduction blocks (MMNCB). Another subgroup of MMNCB may include IgM anti-SGPG antibodies that do not cross-react with MAG. The importance of the fine structure of the epitope has to be considered in view of the pathogenicity of the antibody. It may bear consequences on its binding properties on the neuronal surfaces and on its biological implications.
AB - In peripheral neuropathies with monoclonal gammopathy, mainly IgM, it appears clear from clinical, electrophysiological, and experimental data, that the target glycolipid or glycolipid epitope for the IgM is related to the type of neuropathy - purely sensory, predominantly sensory, or uniquely motor. Investigations have focused on chronic peripheral neuropathies associated with polyclonal IgM reactivity to glycolipids. Although IgM anti-GM1 antibodies are present in normal controls, there is a subgroup of motor neuropathies with high titer anti-GM1 antibodies, mainly multifocal neuropathies with conduction blocks (MMNCB). Another subgroup of MMNCB may include IgM anti-SGPG antibodies that do not cross-react with MAG. The importance of the fine structure of the epitope has to be considered in view of the pathogenicity of the antibody. It may bear consequences on its binding properties on the neuronal surfaces and on its biological implications.
UR - http://www.scopus.com/inward/record.url?scp=0031928621&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031928621&partnerID=8YFLogxK
U2 - 10.1111/j.1749-6632.1998.tb09684.x
DO - 10.1111/j.1749-6632.1998.tb09684.x
M3 - Article
C2 - 9668365
AN - SCOPUS:0031928621
SN - 0077-8923
VL - 845
SP - 322
EP - 329
JO - Annals of the New York Academy of Sciences
JF - Annals of the New York Academy of Sciences
ER -